STAT3 regulates lytic activation of Kaposi's sarcoma-associated herpesvirus

Journal of Virology

Volumn 89, Issue 22, 2015, Pages 11347-11355

  King, Christine A ^a   Li, Xiaofan ^b   Barbachano Guerrero, Arturo ^a   Bhaduri McIntosh, Sumita ^b,c  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR; STAT3 PROTEIN; TRIM28 PROTEIN; UNCLASSIFIED DRUG; 3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; PYRIDINE DERIVATIVE; REPRESSOR PROTEIN; SMALL INTERFERING RNA; STAT3 PROTEIN, HUMAN; TRIM28 PROTEIN, HUMAN; TYRPHOSTIN;

ARTICLE; CELL STIMULATION; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; LIFE CYCLE ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; STIMULUS RESPONSE; VIRUS ACTIVATION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS LYTIC ACTIVATION; VIRUS VIABILITY; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; KAPOSI SARCOMA; METABOLISM; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VIROLOGY; VIRUS LATENCY;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 8, HUMAN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PYRIDINES; REPRESSOR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SARCOMA, KAPOSI; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84945934962     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02008-15     Document Type: Article

References (45)

1. BoshoffC, Weiss R. 2002. AIDS-related malignancies. Nat Rev Cancer 2:373-382. http://dx.doi.org/10.1038/nrc797.
2. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186-1191. http://dx.doi.org/10.1056/NEJM199505043321802.
3. Fields BN, Knipe DM, Howley PM. 1996. Fundamental virology, 3rd ed. Lippincott-Raven, Philadelphia, PA.
4. Okada S, Goto H, Yotsumoto M. 2014. Current status of treatment for primary effusion lymphoma. Intractable Rare Dis Res 3:65-74. http://dx.doi.org/10.5582/irdr.2014.01010.
5. Lan K, Kuppers DA, Verma SC, Robertson ES. 2004. Kaposi's sarcomaassociated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virusmediated control of latency. J Virol 78:6585-6594. http://dx.doi.org/10.1128/JVI.78.12.6585-6594.2004.
6. Li X, Liang D, Lin X, Robertson ES, Lan K. 2011. Kaposi's sarcomaassociated herpesvirus-encoded latency-associated nuclear antigen reduces interleukin-8 expression in endothelial cells and impairs neutrophil chemotaxis by degrading nuclear p65. J Virol 85:8606-8615. http://dx.doi.org/10.1128/JVI.00733-11.
7. Boneschi V, Brambilla L, Berti E, Ferrucci S, Corbellino M, Parravicini C, Fossati S. 2001. Human herpesvirus 8 DNA in the skin and blood of patients with Mediterranean Kaposi's sarcoma: clinical correlations. Dermatology 203:19-23. http://dx.doi.org/10.1159/000051697.
8. Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, Gudza I, Fitzpatrick L, Schooley RT. 2000. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 14:2109-2116. http://dx.doi.org/10.1097/00002030-200009290-00006.
9. Casper C, Nichols WG, Huang ML, Corey L, Wald A. 2004. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103:1632-1634. http://dx.doi.org/10.1182/blood-2003-05-1721.
10. Chen J, Ueda K, Sakakibara S, Okuno T, Parravicini C, Corbellino M, Yamanishi K. 2001. Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator. Proc Natl Acad Sci U S A 98:4119-4124. http://dx.doi.org/10.1073/pnas.051004198.
11. Fardet L, Blum L, Kerob D, Agbalika F, Galicier L, Dupuy A, Lafaurie M, Meignin V, Morel P, Lebbe C. 2003. Human herpesvirus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virusinfected patients. Clin Infect Dis 37:285-291. http://dx.doi.org/10.1086/375224.
12. Grandadam M, Dupin N, Calvez V, Gorin I, Blum L, Kernbaum S, Sicard D, Buisson Y, Agut H, Escande JP, Huraux JM. 1997. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 175:1198-1201. http://dx.doi.org/10.1086/593567.
13. Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, Agbalika F. 2000. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 96:2069-2073.
14. Jones JL, Hanson DL, Chu SY, Ward JW, Jaffe HW. 1995. AIDSassociated Kaposi's sarcoma. Science 267:1078-1079. http://dx.doi.org/10.1126/science.7855583.
15. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. 1999. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340:1063-1070.
16. Robles R, Lugo D, Gee L, Jacobson MA. 1999. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 20:34-38. http://dx.doi.org/10.1097/00042560-199901010-00005.
17. Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. 2006. A nonchemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol 17:1849-1850. http://dx.doi.org/10.1093/annonc/mdl139.
18. Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. 2001. Longterm remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 15:280-282. http://dx.doi.org/10.1097/00002030-200101260-00023.
19. Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, Re A, Ravazzini L, Potenza L, Riva G, Morselli M, Longo G, Cavanna L, Roncaglia R, Torelli G. 2005. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 19:473-476. http://dx.doi.org/10.1038/sj.leu.2403646.
20. Li Q, He M, Zhou F, Ye F, Gao SJ. 2014. Activation of Kaposi's sarcomaassociated herpesvirus (KSHV) by inhibitors of class III histone deacetylases: identification of sirtuin 1 as a regulator of the KSHV life cycle. J Virol 88:6355-6367. http://dx.doi.org/10.1128/JVI.00219-14.
21. Daigle D, Megyola C, El-Guindy A, Gradoville L, Tuck D, Miller G, Bhaduri-McIntosh S. 2010. Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J Virol 84:993-1004. http://dx.doi.org/10.1128/JVI.01745-09.
22. Hill ER, Koganti S, Zhi J, Megyola C, Freeman AF, Palendira U, Tangye SG, Farrell PJ, Bhaduri-McIntosh S. 2013. Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes. J Virol 87:11438-11446. http://dx.doi.org/10.1128/JVI.01762-13.
23. Aoki Y, Feldman GM, Tosato G. 2003. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101:1535-1542. http://dx.doi.org/10.1182/blood-2002-07-2130.
24. Cimica V, Chen HC, Iyer JK, Reich NC. 2011. Dynamics of the STAT3 transcription factor: nuclear import dependent on Ran and importin-beta1. PLoS One 6:e20188. http://dx.doi.org/10.1371/journal.pone.0020188.
25. Liu S, Bekker-Jensen S, Mailand N, Lukas C, Bartek J, Lukas J. 2006. Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation. Mol Cell Biol 26:6056-6064. http://dx.doi.org/10.1128/MCB.00492-06.
26. Zhu L, Puri V, Chandran B. 1999. Characterization of human herpesvirus-8 K8.1A/B glycoproteins by monoclonal antibodies. Virology 262: 237-249. http://dx.doi.org/10.1006/viro.1999.9900.
27. Yu H, Kortylewski M, Pardoll D. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41-51. http://dx.doi.org/10.1038/nri1995.
28. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, Stark GR. 2005. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65:939-947.
29. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y. 2007. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26:2435-2444. http://dx.doi.org/10.1038/sj.onc.1210031.
30. Koganti S, Hui-Yuen J, McAllister S, Gardner B, Grasser F, Palendira U, Tangye SG, Freeman AF, Bhaduri-McIntosh S. 2014. STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation. Proc Natl Acad Sci U S A 111:4946-4951. http://dx.doi.org/10.1073/pnas.1400683111.
31. ENCODE Project Consortium. 2011. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 9:e1001046. http://dx.doi.org/10.1371/journal.pbio.1001046.
32. Chang PC, Fitzgerald LD, Van Geelen A, Izumiya Y, Ellison TJ, Wang DH, Ann DK, Luciw PA, Kung HJ. 2009. Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi's sarcomaassociated herpesvirus and its modulation by the viral protein kinase. Cancer Res 69:5681-5689. http://dx.doi.org/10.1158/0008-5472.CAN-08-4570.
33. Gjyshi O, Roy A, Dutta S, Veettil MV, Dutta D, Chandran B. 2015. Activated Nrf2 Interacts with Kaposi's sarcoma-associated herpesvirus latency protein LANA-1 and host protein KAP1 to mediate global lytic gene repression. J Virol 89:7874-7892. http://dx.doi.org/10.1128/JVI.00895-15.
34. Rauwel B, Jang SM, Cassano M, Kapopoulou A, Barde I, Trono D. 7 April 2015. Release of human cytomegalovirus from latency by a KAP1/TRIM28 phosphorylation switch. eLife. http://dx.doi.org/10.7554/eLife.06068.
35. Sun R, Liang D, Gao Y, Lan K. 2014. Kaposi's sarcoma-associated herpesvirus-encoded LANA interacts with host KAP1 to facilitate establishment of viral latency. J Virol 88:7331-7344. http://dx.doi.org/10.1128/JVI.00596-14.
36. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM. 1996. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88:645-656.
37. King CA. 2013. Kaposi's sarcoma-associated herpesvirus kaposin B induces unique monophosphorylation of STAT3 at serine 727 and MK2-mediated inactivation of the STAT3 transcriptional repressor TRIM28. J Virol 87:8779-8791. http://dx.doi.org/10.1128/JVI.02976-12.
38. Koganti S, Clark C, Zhi J, Li X, Chen EI, Chakrabortty S, Hill ER, Bhaduri-McIntosh S. 2015. Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr virus lytic activation in B lymphocytes. J Virol 89: 5002-5011. http://dx.doi.org/10.1128/JVI.00121-15.
39. Koganti S, de la Paz A, Freeman AF, Bhaduri-McIntosh S. 2014. B lymphocytes from patients with hypomorphic mutation in STAT3 resist Epstein-Barr virus-driven cell proliferation. J Virol 88:516-524. http://dx.doi.org/10.1128/JVI.02601-13.
40. Zhang H, Hu H, Greeley N, Jin J, Matthews AJ, Ohashi E, Caetano MS, Li HS, Wu X, Mandal PK, McMurray JS, Moghaddam SJ, Sun SC, Watowich SS. 2014. STAT3 restrains RANK-and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13. Nat Commun 5:5798. http://dx.doi.org/10.1038/ncomms6798.
41. Darnell JE, Jr. 2002. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740-749. http://dx.doi.org/10.1038/nrc906.
42. Yu H, Jove R. 2004. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4:97-105. http://dx.doi.org/10.1038/nrc1275.
43. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA. 1997. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 272:19625-19631. http://dx.doi.org/10.1074/jbc.272.31.19625.
44. Punjabi AS, Carroll PA, Chen L, LagunoffM. 2007. Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Virol 81:2449-2458. http://dx.doi.org/10.1128/JVI.01769-06.
45. Du T, Zhou G, Roizman B. 2013. Modulation of reactivation of latent herpes simplex virus 1 in ganglionic organ cultures by p300/CBP and STAT3. Proc Natl Acad Sci U S A 110:E2621-E2628. http://dx.doi.org/10.1073/pnas.1309906110.